BioNTech Results Presentation Deck

We plan to initiate multiple FIH¹ trials for our preclinical product candidates in 2021 Drug class Platform Oncology mRNA 13 Cell Therapies mRNA Fix Vac RiboMabs (mRNA-encoded antibodies) RiboCytokines (mRNA-encoded Cytokines) CAR-T Cells Neoantigen-based T cell therapy TCRs Infectious Disease Immunotherapies Rare Disease PRT² Product Candidate BNT116 BNT141 BNT142 BNT151 BNT 152, BNT153 BNT211 BNT212 BNT221 (NEO-PTC-01) to be selected BNT 161 undisclosed undisclosed BNT171 undisclosed Indication (Targets) NSCLC multiple solid tumors multiple solid tumors (CD3+CLDN6) multiple solid tumors (optimized IL-2) multiple solid tumors (IL-7, IL-2) multiple solid tumors (CLDN6) pancreatic, other cancers (CLDN18.2) multiple solid tumors all tumors influenza up to 10 indications HIV and tuberculosis not disclosed 4 additional rare disease indications ¹ FIH = First in Human; 2 PRT = Protein Replacement Therapy; 3 We are eligible to receive worldwide licenses Rights Collaborator fully-owned fully-owned fully-owned fully-owned Pfizer Penn³ Milestones fully-owned Phase 1 start in 1H 2021 Bill & Melinda Gates Foundation Phase 1 start in 1H 2021 Phase 1 start in 2H 2021 fully-owned Phase 1/2a start in 2H 2020 fully-owned fully-owned Phase 1 start in 1H 2021 fully-owned Genevant (global 50:50 profit/loss) Phase 1 start in 1H 2021 We expect to initiate multiple Phase 1 trials in 2021 BIONTECH

View entire presentation